The Evolving Therapeutic Landscape for HER2-Positive Early-Stage Breast Cancer

Download this slideset from Lee Schwartzberg, MD, FACP to review key data on optimal treatment for HER2-positive early breast cancer, including neoadjuvant and adjuvant therapy.
Lee Schwartzberg, MD, FACP
Format: Microsoft PowerPoint (.ppt)
File Size: 1,005 KB
Released: August 10, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Puma Biotechnology

Related Content

Commentary from Nelson F. Sanchez, MD, on caring for transgender individuals, from the healthcare disparities they face to how healthcare professionals can improve their care, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD Released: June 28, 2022

Results from LUMINA trial showing very low local recurrence rate with omission of radiotherapy after breast-conserving surgery in patients with low-risk luminal A breast cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 15, 2022

Exploratory analysis of EFS by residual cancer burden from KEYNOTE-522 evaluating neoadj pembrolizumab plus chemotherapy followed by adj pembrolizumab for early-stage TNBC, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 14, 2022

PALOMA-2 study: final OS analysis with palbociclib plus letrozole in ER-positive/HER2-negative advanced breast cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 10, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings